# FGFR2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - FGFR2 is a transmembrane receptor tyrosine kinase critical for embryonic development and tissue homeostasis, with distinct epithelial (FGFR2b) and mesenchymal (FGFR2c) isoforms dictated by alternative splicing of exons IIIb/IIIc, regulated by ESRP1/2. - Germline mutations in FGFR2, particularly in the extracellular domains (e.g., S252W, P253R in Apert syndrome), cause autosomal dominant craniosynostosis syndromes by promoting constitutive receptor activation. - Somatic alterations in FGFR2, including gene fusions (e.g., with BICC1 in iCCA) and activating point mutations (e.g., N550K in the kinase domain), are oncogenic drivers in intrahepatic cholangiocarcinoma, gastric cancer, and endometrial cancer. - FDA-approved targeted therapies like pemigatinib, infigratinib, and futibatinib are selective FGFR inhibitors used for FGFR2-altered cholangiocarcinoma, with next-generation agents and combination strategies addressing resistance mechanisms such as secondary kinase domain mutations. - FGFR2 signaling pathways, including RAS-MAPK, PI3K-AKT, and PLCγ, are activated downstream of receptor dimerization and autophosphorylation, mediating cellular proliferation, differentiation, and survival. - Beyond cancer, germline FGFR2 variants are implicated in craniosynostosis syndromes and rare associations with autism spectrum disorder, highlighting its broad impact on human development and health. --- ## Executive Summary & Key Metadata The **Fibroblast Growth Factor Receptor 2 (FGFR2)** gene encodes a transmembrane receptor tyrosine kinase (RTK) that serves as a high-affinity receptor for multiple fibroblast growth factors (FGFs). FGFR2 is a master regulator of embryonic development, tissue homeostasis, and cellular differentiation, with context-dependent roles in osteogenesis, myogenesis, angiogenesis, and epithelial-mesenchymal signaling. Germline mutations in FGFR2 produce a spectrum of autosomal dominant craniosynostosis syndromes, while somatic alterations—including gene amplification, activating point mutations, and oncogenic chromosomal fusions—drive the pathogenesis of multiple solid tumors, most notably intrahepatic cholangiocarcinoma (iCCA), gastric cancer, and endometrial cancer. The clinical relevance of FGFR2 is underscored by the FDA approval of selective FGFR inhibitors for FGFR2-altered malignancies and the active development of next-generation inhibitors designed to overcome acquired resistance. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | FGFR2 | | **UniProt Accession** | P21802 | | **Representative PDB ID** | true (multiple structures available; e.g., 3CLY, 3OJM) | | **Chromosomal Locus** | 10q26.13 (GRCh38: chr10:121,478,330-121,598,458) | | **Primary Molecular Function** | Receptor tyrosine kinase; FGF binding; signal transduction via RAS-MAPK, PI3K-AKT, PLCγ, and STAT pathways | | **Disease & Pathology Associations** | Apert, Crouzon, Pfeiffer, Beare-Stevenson, Jackson-Weiss syndromes; intrahepatic cholangiocarcinoma; gastric cancer; endometrial cancer; breast cancer; glioblastoma; autism spectrum disorder | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *FGFR2* gene is located on the long arm of chromosome 10 at cytogenetic band **10q26.13**. The gene spans approximately 120 kilobases of genomic DNA and consists of **22 exons** (including alternative exons IIIb and IIIc) that encode a protein of 821 amino acids in its canonical isoform. The genomic organization of *FGFR2* is highly conserved across vertebrates, and comparative analysis of the human FGFR gene family (FGFR1-4) reveals a shared ancestral architecture characterized by an N-terminal signal peptide, three extracellular immunoglobulin (Ig)-like domains (D1, D2, D3), a transmembrane helix, and a split intracellular tyrosine kinase domain. The *FGFR2* locus is situated in a gene-dense region of chromosome 10q, with the *ATRNL1* gene located telomerically and *BICC1* located centromerically. Notably, *BICC1* is a frequent fusion partner of *FGFR2* in iCCA, and the proximity of these loci may facilitate the genomic rearrangements that generate oncogenic fusion transcripts. The promoter region of *FGFR2* lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for transcription factors including SP1, AP-2, and ETS family members. Three novel functional polymorphisms in the promoter region have been identified and associated with breast cancer risk, suggesting that cis-regulatory variation at this locus modulates gene expression in a tissue-specific manner. ### 1.2 Alternative Splicing and Isoform Diversity The most biologically significant feature of *FGFR2* is the mutually exclusive alternative splicing of exons **IIIb** and **IIIc** (exons 8 and 9, respectively), which encode the C-terminal half of the third immunoglobulin-like domain (D3). This splicing event is regulated by the epithelial splicing regulatory proteins **ESRP1** and **ESRP2**, which promote inclusion of exon IIIb in epithelial cells and exclusion in mesenchymal cells. The resulting isoforms exhibit distinct ligand-binding specificities: - **FGFR2-IIIb (FGFR2b)**: Expressed predominantly in epithelial cells; binds FGF1, FGF3, FGF7 (KGF), FGF10, and FGF22. This isoform is critical for epithelial-mesenchymal interactions during organogenesis. - **FGFR2-IIIc (FGFR2c)**: Expressed predominantly in mesenchymal cells; binds FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, FGF17, and FGF18. This isoform mediates paracrine signaling from epithelial to mesenchymal compartments. The switch between IIIb and IIIc isoforms is developmentally regulated and frequently dysregulated in cancer. Downregulation of ESRP1/2 in bladder carcinoma promotes a shift toward the IIIc isoform, which correlates with increased lung metastasis and altered macrophage polarization. In addition to the IIIb/IIIc switch, *FGFR2* undergoes alternative splicing in the 5' untranslated region and produces multiple transcript variants through the use of alternative polyadenylation signals. The gene also generates a circular RNA (circFGFR2) that functions as a microRNA sponge, sequestering miR-133a-5p and miR-29b-1-5p to promote myoblast proliferation and differentiation. ### 1.3 Epigenetic Regulation The *FGFR2* promoter is subject to DNA methylation, and aberrant hypermethylation has been documented in gastric cancer cell lines, leading to transcriptional silencing. Conversely, hypomethylation of *FGFR2* in placental tissue is associated with high birth weight centile, indicating that epigenetic regulation of this locus influences fetal growth. In gastric cancer, methylation status may serve as a blood-based epigenetic biomarker, with differential methylation patterns detectable in circulating cell-free DNA. The complex interplay between promoter methylation, histone modifications, and transcription factor occupancy at the *FGFR2* locus remains an active area of investigation. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The FGFR2 protein is a single-pass type I transmembrane receptor with the following domain architecture from N-terminus to C-terminus: 1. **Signal Peptide** (residues 1-21): Directs co-translational translocation into the endoplasmic reticulum. 2. **Immunoglobulin-like Domain D1** (residues 22-136): Involved in receptor autoinhibition through intramolecular interactions with D2; contains the "acid box" motif (residues 107-117) that contributes to autoinhibitory regulation. 3. **Immunoglobulin-like Domain D2** (residues 137-246): Primary FGF-binding domain; contains the heparin/heparan sulfate binding site. 4. **Immunoglobulin-like Domain D3** (residues 247-360): Determines ligand-binding specificity; encoded by exons IIIb or IIIc depending on splicing. 5. **Transmembrane Helix** (residues 361-383): Hydrophobic α-helix anchoring the receptor in the plasma membrane. 6. **Juxtamembrane Region** (residues 384-430): Contains regulatory tyrosine residues and binding sites for signaling adaptors. 7. **Split Tyrosine Kinase Domain** (residues 431-766): Composed of an N-terminal lobe (residues 431-520), a hinge region, and a C-terminal lobe (residues 521-766); contains the ATP-binding pocket and catalytic residues. 8. **C-terminal Tail** (residues 767-821): Contains multiple autophosphorylation sites and docking sites for downstream signaling proteins. ### 2.2 Structural Basis of Ligand Binding and Receptor Activation The extracellular region of FGFR2 adopts a modular architecture in which D2 and D3 form a contiguous FGF-binding pocket. Ligand binding induces receptor dimerization, which is stabilized by interactions between the D2 domains of two receptor molecules and by the bridging action of heparan sulfate proteoglycans (HSPGs). The crystal structure of FGFR2 in complex with FGF2 and heparin reveals a 2:2:2 stoichiometry in which two FGF ligands bind symmetrically to two receptor molecules, with heparin contacting both ligands and both receptors to stabilize the signaling complex. The autoinhibitory conformation of FGFR2 is maintained by intramolecular interactions between D1 and D2, which occlude the ligand-binding site. Heparin binding disrupts this autoinhibition by inducing a conformational change that exposes the FGF-binding surface. This "two-state" model of receptor regulation explains the requirement for HSPGs in high-affinity FGF signaling and provides a structural rationale for the gain-of-function effects of many pathogenic mutations that destabilize the autoinhibited conformation. ### 2.3 Structural Impact of Pathogenic Mutations Missense mutations associated with craniosynostosis syndromes cluster in specific structural regions of FGFR2. The two canonical Apert syndrome mutations, **Ser252Trp** and **Pro253Arg**, are located in the linker region between D2 and D3 (residues 252-253) and disrupt the autoinhibitory interface, leading to constitutive ligand-independent receptor activation. The **Cys278Phe** and **Cys342Arg** mutations, associated with Crouzon and Pfeiffer syndromes, respectively, create unpaired cysteine residues that promote aberrant disulfide-bonded receptor dimerization. The **Ala344Pro** mutation, found in both Crouzon and Pfeiffer syndromes, introduces a rigid proline residue into the D3 domain, destabilizing the immunoglobulin fold and promoting ligand-independent activation. Somatic mutations in cancer frequently target the kinase domain. The **Asn550Lys** mutation in the N-terminal lobe of the kinase domain enhances ATP binding and increases catalytic activity. The **Lys659Glu** mutation in the C-terminal lobe disrupts autoinhibitory interactions and promotes constitutive kinase activation. Structural studies of these mutants reveal that they stabilize the active "DFG-in" conformation of the kinase domain, increasing the affinity for ATP and reducing the threshold for activation. > **[Interactive 3D Protein Visualizer: Load FGFR2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P21802)** > > Use the interactive viewer to explore the three-dimensional architecture of FGFR2. The tool loads experimentally determined structures from the RCSB PDB and allows you to: > - Color residues by domain (D1, D2, D3, kinase N-lobe, kinase C-lobe) > - Highlight pathogenic mutation hotspots (e.g., S252W, P253R, C278F, A344P) > - Visualize the ATP-binding pocket and docked inhibitors > - Measure distances between key catalytic residues > - Superimpose the IIIb and IIIc isoforms to compare ligand-binding surfaces ### 2.4 Post-Translational Modifications FGFR2 undergoes extensive post-translational modification that regulates its trafficking, stability, and signaling output. N-linked glycosylation at multiple sites in the extracellular domain is required for proper folding and cell-surface expression. The receptor is also modified by O-linked glycosylation in the juxtamembrane region, which modulates interactions with the extracellular matrix. Ligand-induced activation triggers autophosphorylation of at least seven tyrosine residues (Tyr463, Tyr583, Tyr585, Tyr653, Tyr654, Tyr730, and Tyr769), which create docking sites for SH2-domain-containing proteins including PLCγ, GRB2, and SHC. Ubiquitination by the E3 ligase CBL targets the activated receptor for endocytosis and lysosomal degradation, providing a critical negative feedback mechanism that terminates signaling. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical FGF Signaling Cascades FGFR2 activation initiates a cascade of intracellular signaling events that regulate proliferation, differentiation, migration, and survival. The principal downstream pathways include: **RAS-MAPK Pathway**: Upon ligand-induced receptor dimerization and autophosphorylation, the adaptor protein GRB2 binds to phosphorylated tyrosine residues either directly or through the scaffold protein FRS2α. GRB2 recruits the guanine nucleotide exchange factor SOS to the plasma membrane, where it activates RAS by promoting GDP-GTP exchange. GTP-bound RAS activates RAF, which phosphorylates and activates MEK1/2, which in turn phosphorylates and activates ERK1/2. Activated ERK translocates to the nucleus and phosphorylates transcription factors including ELK1, c-FOS, and c-JUN, driving expression of genes involved in cell cycle progression and differentiation. **PI3K-AKT Pathway**: GRB2-associated binder (GAB) proteins, recruited to FRS2α, activate phosphoinositide 3-kinase (PI3K), which generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the plasma membrane. PIP3 recruits AKT to the membrane, where it is phosphorylated and activated by PDK1 and mTORC2. Active AKT phosphorylates multiple substrates, including BAD, FOXO transcription factors, and MDM2, promoting cell survival and proliferation. **PLCγ Pathway**: Phospholipase Cγ (PLCγ) binds directly to phosphorylated Tyr766 in the C-terminal tail of FGFR2. PLCγ hydrolyzes phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate (IP3). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC), which modulates ion channel activity and gene expression. **STAT Pathway**: FGFR2 can directly activate signal transducer and activator of transcription (STAT) proteins, particularly STAT3 and STAT5, through phosphorylation by the receptor kinase domain. Activated STATs dimerize and translocate to the nucleus, where they regulate genes involved in inflammation, angiogenesis, and immune evasion. ### 3.2 Non-Canonical and Nuclear Functions Beyond canonical RTK signaling at the plasma membrane, FGFR2 exhibits non-canonical functions that contribute to its biological complexity. A fraction of FGFR2 undergoes regulated intramembrane proteolysis (RIP), generating a soluble intracellular domain that translocates to the nucleus. Nuclear FGFR2 interacts with the MLL-AF4 oncogenic chimera in t(4;11) leukemia cells and positively regulates HOXA9 gene expression, revealing a direct transcriptional role for FGFR2 in leukemogenesis. This nuclear function is independent of the receptor's kinase activity and involves direct protein-protein interactions with chromatin-associated factors. FGFR2 also engages in crosstalk with other signaling pathways. In endometrial cancer, FGFR2 mutations promote tumor progression through dual engagement of EGFR and Notch signaling pathways. The mutant receptor activates EGFR through transactivation mechanisms and upregulates Notch ligands, creating a signaling network that sustains tumor growth and invasion. In cholangiocarcinoma, FGFR2 signaling activates the AKT/mTOR pathway and induces epithelial-mesenchymal transition (EMT), contributing to chemoresistance. ### 3.3 Protein-Protein Interaction Network The FGFR2 interactome is extensive and includes both positive and negative regulators of signaling. Key interaction partners identified through affinity purification-mass spectrometry and yeast two-hybrid screens include: | **Interactor** | **Function** | **Interaction Domain** | |---|---|---| | FRS2α | Scaffold protein; couples receptor to RAS-MAPK | Phosphotyrosine binding (PTB) domain | | GRB2 | Adaptor protein; recruits SOS | SH2 domain | | PLCγ | Phospholipase; generates second messengers | SH2 domain | | SHC | Adaptor protein; activates RAS | PTB domain | | CBL | E3 ubiquitin ligase; mediates receptor degradation | RING finger domain | | SHP2 | Protein tyrosine phosphatase; amplifies MAPK signaling | SH2 domains | | STAT3/5 | Transcription factors; direct signaling effectors | SH2 domain | | Heparan sulfate | Co-factor; stabilizes ligand-receptor complex | D2 domain | | FGF ligands | Activating ligands | D2-D3 interface | | FGFR2 itself | Homodimerization | D2 domain | The STRING database analysis of FGFR2 reveals a high-confidence interaction network (combined score >0.9) with FRS2, GRB2, PLCG1, and multiple FGF ligands. BioGRID lists over 100 physical interactions for FGFR2, including both activating and inhibitory partners. ### 3.4 Physiological Functions FGFR2 signaling is essential for embryonic development and adult tissue homeostasis. During embryogenesis, FGFR2-IIIb mediates epithelial-mesenchymal interactions required for limb bud formation, lung branching morphogenesis, salivary gland development, and skin appendage formation. FGFR2-IIIc regulates osteoblast differentiation and endochondral bone formation, with mutations causing premature suture fusion in craniosynostosis syndromes. In the adult, FGFR2 maintains epithelial homeostasis in the skin, gut, and reproductive tract. In salivary glands, FGFR2 is essential for duct homeostasis and MAPK-dependent seromucous acinar cell differentiation. In the brain, FGFR2 expression is developmentally regulated and contributes to synaptic plasticity, with dysregulation implicated in autism spectrum disorder and major depression. ```mermaid sequenceDiagram participant FGF as "FGF Ligand" participant HSPG as "Heparan Sulfate" participant R as "FGFR2 Receptor" participant FRS as "FRS2α" participant GRB as "GRB2/SOS" participant RAS as "RAS" participant RAF as "RAF" participant MEK as "MEK1/2" participant ERK as "ERK1/2" participant NUC as "Nucleus" FGF->>HSPG: Bind HSPG->>R: Present ligand FGF->>R: Bind D2-D3 pocket R->>R: Dimerization & autophosphorylation R->>FRS: Recruit & phosphorylate FRS->>GRB: Recruit GRB->>RAS: Activate (GDP→GTP) RAS->>RAF: Activate RAF->>MEK: Phosphorylate MEK->>ERK: Phosphorylate ERK->>NUC: Translocate NUC->>NUC: Phosphorylate transcription factors NUC->>NUC: Drive proliferation/differentiation genes ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations in Craniosynostosis Syndromes Germline mutations in *FGFR2* cause a spectrum of autosomal dominant craniosynostosis syndromes characterized by premature fusion of cranial sutures, midface hypoplasia, and variable limb anomalies. The major syndromes and their associated mutations include: **Apert Syndrome**: Characterized by coronal craniosynostosis, severe syndactyly of the hands and feet, and midface hypoplasia. Two missense mutations account for nearly all cases: **Ser252Trp** (c.755C>G) and **Pro253Arg** (c.758C>G) in the linker between D2 and D3. These mutations create a gain-of-function receptor with enhanced ligand-binding affinity and altered FGF specificity. The Ser252Trp mutation is associated with more severe cleft palate, while Pro253Arg correlates with more severe syndactyly. The mutations have been identified across diverse ethnic populations, including Indonesian, Mexican, and Colombian patients. **Crouzon Syndrome**: Characterized by craniosynostosis, ocular proptosis, and midface hypoplasia without significant limb anomalies. More than 30 distinct mutations have been identified, with hotspots at **Cys278Phe**, **Cys342Arg/Ser/Tyr**, and **Ala344Pro**. The Cys342 mutations create unpaired cysteines that promote aberrant disulfide-bonded receptor dimerization and constitutive activation. A synonymous mutation in the IIIc exon activates a cryptic 5' splice site, leading to exon skipping and altered receptor function. A novel insertion in the *FGFR2* gene has been reported in a patient with Crouzon phenotype and sacrococcygeal tail. An inherited mutation (Cys278Phe) has been shown to increase osteogenesis gene expression, directly linking the molecular defect to the clinical phenotype. **Pfeiffer Syndrome**: Characterized by craniosynostosis, broad thumbs and great toes, and variable syndactyly. Mutations cluster in the D3 domain and include **Trp290Cys**, **Tyr340Cys**, **Cys342Arg**, and **Ala344Pro**. The **Gln289Pro** mutation has been reported in both Pfeiffer syndrome and Saethre-Chotzen syndrome, demonstrating phenotypic heterogeneity and variable expressivity. A novel **Cys278Leu** mutation (c.833_834GC>TG) was identified in a Korean patient with Pfeiffer syndrome. The mutational spectrum of Pfeiffer syndrome has been extensively characterized, with genotype-phenotype correlations revealing that mutations in the D3 domain generally produce more severe phenotypes. **Beare-Stevenson Cutis Gyrata Syndrome**: Characterized by craniosynostosis, cutis gyrata (furrowed skin), acanthosis nigricans, and craniofacial anomalies. Mutations include **Tyr375Cys** and **Ser372Tyr** in the transmembrane domain, which promote constitutive receptor dimerization. **Jackson-Weiss Syndrome**: Characterized by craniosynostosis and foot anomalies. Mutations overlap with those found in Crouzon and Pfeiffer syndromes, demonstrating that identical mutations can produce different clinical phenotypes. **Genotype-Phenotype Correlations**: The identical mutations in *FGFR2* can cause both Pfeiffer and Crouzon syndrome phenotypes, indicating that modifier genes and environmental factors influence clinical expression. A novel mutation at the same codon as Crouzon syndrome mutations (Ala344Pro) produces severe Pfeiffer syndrome type 2, highlighting the variable expressivity of FGFR2 mutations. The **Cys278Phe** mutation has been shown to cause both Apert and Crouzon syndromes in different patients, further demonstrating the clinical heterogeneity associated with FGFR2 mutations. ### 4.2 Somatic Mutations in Cancer **Intrahepatic Cholangiocarcinoma (iCCA)**: FGFR2 alterations are among the most clinically actionable genomic events in iCCA, occurring in 10-16% of cases. The predominant alteration is gene fusion, with more than 20 distinct fusion partners identified, including *BICC1*, *AHCYL1*, *TACC3*, *KIAA1217*, *OFD1*, and *CCDC6*. These fusions typically retain the N-terminal ligand-binding domain and the kinase domain while replacing the C-terminal tail, resulting in constitutive dimerization and ligand-independent activation. FGFR2 fusions are enriched in the small duct subtype of iCCA and are associated with distinct clinicopathological features. Patients with FGFR2 fusions who undergo curative-intent resection may have improved survival compared to wild-type patients, suggesting that this molecular subtype represents a distinct biological entity. **Gastric Cancer**: FGFR2 gene amplification occurs in 2-10% of gastric cancers and is associated with poor prognosis and resistance to chemotherapy. Amplification is more frequent in diffuse-type gastric cancer and correlates with FGFR2 protein overexpression. High-level amplification predicts sensitivity to FGFR inhibitors in preclinical models. The SNU-16 gastric cancer cell line harbors the *APIP-FGFR2* fusion gene with heterogeneous genomic breakpoints, demonstrating the genomic complexity of FGFR2 alterations in gastric cancer. FGFR2 polysomy and gene amplification define a molecular subtype that may benefit from FGFR-targeted therapy. **Endometrial Cancer**: FGFR2 mutations occur in approximately 10-16% of endometrial cancers, with hotspots at **Ser252Trp**, **Pro253Arg**, and **Asn550Lys**. These mutations promote tumor progression through dual engagement of EGFR and Notch signaling pathways, leading to increased proliferation, invasion, and metastasis. FGFR2 mutations are associated with advanced stage and reduced survival, establishing the receptor as a prognostic biomarker and therapeutic target. **Breast Cancer**: FGFR2 single nucleotide polymorphisms (SNPs) are among the most consistently replicated genetic risk factors for breast cancer. The intronic SNP **rs2981582** is associated with increased breast cancer risk across multiple ethnic populations, including Chinese, Mexican, Bangladeshi, and Siberian cohorts. The risk allele is associated with increased FGFR2 expression in breast tissue, suggesting that the SNP resides in an enhancer element that modulates gene transcription. The association is stronger for estrogen receptor-positive tumors and interacts with postmenopausal hormone therapy and dietary patterns. Three novel functional polymorphisms in the promoter region have been identified and meta-analyzed for breast cancer risk. The FGFR2 SNP rs2981582 has also been studied in laryngeal squamous cell carcinoma, with genotype frequencies differing from healthy controls. **Glioblastoma**: FGFR2 alterations, including fusions and amplifications, define a molecular subgroup of glioblastoma with aggressive phenotype and distinct gene expression programs. Multiple TERT and FGFR2 gene fusions have been identified in a pineal region glioblastoma, suggesting that FGFR2 alterations cooperate with telomerase dysregulation in gliomagenesis. **Other Malignancies**: FGFR2 fusions have been identified in calcified chondroid mesenchymal neoplasms (with FN1 as fusion partner), prostate cancer (KLK2-FGFR2), rhabdomyosarcoma, and bladder carcinoma. In rhabdomyosarcoma, FGF7-FGFR2 autocrine signaling increases growth and chemoresistance. In bladder carcinoma, downregulated ESRP1/2 promotes lung metastasis through altering FGFR2 splicing and macrophage polarization. ### 4.3 Non-Cancer Pathologies **Autism Spectrum Disorder (ASD)**: FGFR2 has been identified as a new gene involved in the genesis of autism spectrum disorder. Rare pathogenic variants in FGFR2 have been identified in ASD patients, and the receptor's role in synaptic plasticity and neuronal development provides a biological rationale for this association. **Acute Myeloid Leukemia (AML)**: A genome-wide haplotype association study identified FGFR2 as a risk gene for AML, suggesting that common genetic variation at this locus influences susceptibility to myeloid malignancies. **Bone Mineral Density**: FGFR2 gene polymorphisms are associated with femoral neck bone mineral density in the Chinese Han population, indicating a role in skeletal homeostasis beyond craniosynostosis. **Depression**: The Negr1-Fgfr2 pathway is altered by antidepressant treatment, linking FGFR2 signaling to mood regulation and antidepressant response. --- ## 5. Host-Pathogen & Viral Interactions The FGFR2 gene product does not serve as a primary receptor for any known human pathogen. However, several indirect interactions between pathogens and FGFR2 signaling have been documented: **Viral Oncoproteins**: The MLL-AF4 oncogenic chimera, generated by the t(4;11) chromosomal translocation in infant acute lymphoblastic leukemia, interacts with nuclear FGFR2 and positively regulates HOXA9 gene expression. While MLL-AF4 is not a viral protein, this interaction demonstrates that oncogenic chimeras can hijack FGFR2's nuclear functions to drive leukemogenesis. **FGF Signaling in Viral Infection**: Several viruses, including hepatitis B and C viruses, modulate FGF signaling to promote hepatocellular carcinoma. While direct interactions with FGFR2 have not been demonstrated, the receptor's role in liver regeneration and fibrosis suggests that viral hepatitis may indirectly influence FGFR2 signaling. **Immune Evasion**: FGFR2 signaling in the tumor microenvironment promotes immune evasion through multiple mechanisms. FGFR2 activation upregulates PD-L1 expression on tumor cells and promotes an immunosuppressive tumor microenvironment characterized by M2 macrophage polarization. FGFR2 fusions in cholangiocarcinoma generate neoantigens that can be recognized by tumor-infiltrating lymphocytes, providing a rationale for adoptive cell therapy approaches. **Bacterial Effectors**: No direct interactions between bacterial effectors and FGFR2 have been reported. However, *Helicobacter pylori* infection, a major risk factor for gastric cancer, induces chronic inflammation that may promote FGFR2 amplification and signaling dysregulation in gastric epithelial cells. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 FDA-Approved FGFR Inhibitors **Pemigatinib (PEMAZYRE)**: Pemigatinib is a selective, ATP-competitive inhibitor of FGFR1-3 that received FDA accelerated approval on April 17, 2020, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement. The approval was based on the FIGHT-202 phase 2 trial, which demonstrated an overall response rate of 36% in the FGFR2 fusion/rearrangement cohort. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identified correlates of response and mechanisms of resistance to pemigatinib, including the emergence of polyclonal secondary mutations in the FGFR2 kinase domain. **Infigratinib (TRUSELTIQ)**: Infigratinib (BGJ398) is an oral FGFR1-3 kinase inhibitor that received FDA accelerated approval in May 2021 for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other rearrangements. The approval was based on the phase 2 study demonstrating durable responses in patients with FGFR2-altered cholangiocarcinoma. The PROOF 301 trial is evaluating infigratinib versus gemcitabine plus cisplatin as first-line treatment in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations. **Futibatinib (LYTGOBI)**: Futibatinib (TAS-120) is an irreversible, covalent FGFR1-4 inhibitor that received FDA approval in September 2022 for previously treated, unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or other rearrangements. The approval was based on the FOENIX-CCA2 phase 2 trial, which demonstrated an overall response rate of 42%. Futibatinib overcomes resistance to ATP-competitive FGFR inhibitors by covalently binding to Cys491 in the kinase domain, providing activity against tumors with acquired resistance mutations. The FOENIX-CCA3 phase 3 trial is evaluating futibatinib versus gemcitabine-cisplatin as first-line treatment. ### 6.2 Investigational Agents **Derazantinib (ARQ 087)**: Derazantinib is an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity. A phase 1/2 study demonstrated antitumor activity in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma, with an overall response rate of 20.7%. **AZD4547**: AZD4547 is a selective FGFR1-3 inhibitor evaluated in the SHINE study, a randomized, open-label phase 2 trial comparing AZD4547 monotherapy versus paclitaxel in previously treated patients with advanced gastric cancer with FGFR2 polysomy or gene amplification. The trial did not meet its primary endpoint of improved progression-free survival in the overall population, but post-hoc analyses suggested benefit in patients with high-level FGFR2 amplification. **KIN-3248**: KIN-3248 is an irreversible, selective small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary resistance FGFR2/3 alterations. A phase 1 study is evaluating KIN-3248 in patients with advanced FGFR2/3-driven solid tumors. **FPA144 (Bemarituzumab)**: FPA144 is a therapeutic antibody targeting FGFR2 that was developed for treating patients with gastric cancers bearing FGFR2 gene amplification. The antibody is afucosylated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) and has shown preclinical activity against FGFR2-amplified gastric cancer models. ### 6.3 Resistance Mechanisms and Next-Generation Strategies Acquired resistance to FGFR inhibitors is a major clinical challenge. The dominant resistance mechanism is the emergence of polyclonal secondary mutations in the FGFR2 kinase domain, including the "gatekeeper" mutation **Val564Phe** and the **Asn549His/Lys/Thr** mutations in the molecular brake region. These mutations reduce inhibitor binding affinity while preserving or enhancing kinase activity. Irreversible inhibitors such as futibatinib and KIN-3248 that covalently bind to Cys491 can overcome resistance to ATP-competitive inhibitors. Additional resistance mechanisms include activation of bypass signaling pathways (EGFR, MET, PI3K), epithelial-mesenchymal transition, and increased expression of FGF ligands that compete with inhibitor binding. Combination strategies targeting FGFR2 and parallel pathways (e.g., EGFR inhibitors, MEK inhibitors, immune checkpoint inhibitors) are under active investigation. ### 6.4 Gene Therapy and RNA-Based Approaches Targeted allele-specific FGFR2 knockdown using human recombinant ferritin nanoparticles has been developed as a personalized treatment approach for Crouzon syndrome. This strategy delivers antisense oligonucleotides or small interfering RNAs specifically to cells expressing the mutant allele, reducing mutant FGFR2 expression while preserving wild-type receptor function. The approach has shown efficacy in preclinical models and represents a promising avenue for the treatment of gain-of-function FGFR2 mutations. ### 6.5 Liquid Biopsy and Biomarker Development Liquid biopsy approaches for detecting FGFR2 alterations in circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) are under active development. FGFR2 fusions can be detected in plasma from patients with FGFR2 fusion-positive cholangiocarcinoma, and longitudinal monitoring of ctDNA can track treatment response and detect emerging resistance mutations. Electrochemical assays using graphene oxide-loaded magnetic nanoparticles have been developed for the detection of FGFR2:FAM76A fusion gene in circulating tumor RNA. These minimally invasive approaches have the potential to guide treatment selection and monitor disease progression in real time. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Identifier** | **URL** | |---|---|---| | HGNC | 3689 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689 | | NCBI Gene | 2263 | https://www.ncbi.nlm.nih.gov/gene/2263 | | Ensembl | ENSG00000066468 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066468 | | UniProt | P21802 | https://www.uniprot.org/uniprotkb/P21802 | | RCSB PDB | 3CLY, 3OJM, 3RI1 | https://www.rcsb.org/search?q=fgfr2 | | ClinVar | FGFR2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=FGFR2%5Bgene%5D | | COSMIC | FGFR2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGFR2 | | OncoKB | FGFR2 | https://www.oncokb.org/gene/FGFR2 | | STRING | 9606.ENSP00000354315 | https://string-db.org/network/9606.ENSP00000354315 | | BioGRID | 109276 | https://thebiogrid.org/109276 | | Gene Ontology (GO) | GO:0004713, GO:0005007, GO:0048015 | https://www.ebi.ac.uk/QuickGO/ | **Gene Ontology Terms**: - **Molecular Function**: GO:0004713 (protein tyrosine kinase activity), GO:0005007 (fibroblast growth factor receptor activity), GO:0005524 (ATP binding), GO:0042802 (identical protein binding) - **Biological Process**: GO:0048015 (phosphatidylinositol-mediated signaling), GO:0008543 (fibroblast growth factor receptor signaling pathway), GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway), GO:0030154 (cell differentiation), GO:0008283 (cell population proliferation) ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)